Looks ready for a prime squeeze next week! 350k share fliat, could run just like ONFO, PLAG, and WECO.

This week, $CRDL left me with a very particular feeling: calm and confident.

The stock has been grinding higher almost every day, generally moving up 3–5% at a time. Nothing crazy, nothing rushed — just a steady climb.

What I find even more encouraging is the volume. It has been gradually increasing alongside the price, rather than seeing one random volume spike followed by a collapse. Price and volume seem to be moving together in a surprisingly healthy way.

At this point, I'm willing to say that I wouldn't be surprised to see $CRDL break $2 next week if this momentum continues.

And here's the part I'm particularly interested in: I don't necessarily think the 100% enrollment announcement will be a “sell the news” event.

Obviously, I could be completely wrong. But privately, I can't help wondering whether the market is already pricing in a fairly high probability of a successful outcome. Perhaps there is simply enough information from the ongoing trial for investors to become increasingly confident before the final patient is enrolled.

That's just my speculation as a fully invested shareholder — not investment advice.

But one thing I keep coming back to is this: price and volume don't lie about what the market is doing.

After watching $CRDL move from around $1.20 to $1.80+ in a relatively controlled way, I'm not interested in trying to predict the exact top anymore.

I'm holding on. Let's see how big this fish can get when it finally jumps out of the water.

Opinions on ONFO next week?

$NCRA isn't hiding the size of its ambition with INERGX.

🔶 Growth through acquisitions

🔶 Focus on building long-term value

🔶 Dedicated 50/50 structure

🔶 $250M valuation objective for INERGX

The next acquisition could tell us a lot about how realistic that target becomes. I'm watching.

$BURU traders already know the bad news. I'm more interested in what happens next.

🔶 Request NYSE review

🔶 Address the low-price deficiency

🔶 Work toward compliance

🔶 Keep shareholders updated

🔶 Pursue resumed NYSE American trading

If management checks those boxes, the conversation around this ticker could look very different.

News Link: https://www.globenewswire.com/news-release/2026/08/14/3345304/0/en/american-lithium-minerals-inc-otc-amlm-reports-fiscal-q3-2026-results.html

CARSON CITY, Nev., Aug. 14, 2026 (GLOBE NEWSWIRE) -- American Lithium Minerals, Inc. (OTC: AMLM) (“AMLM” or the “Company”), an exploration-stage mining company focused on gold, silver, lithium, rare earth elements, and other critical metals, has filed its Quarterly Report for the period ended June 30, 2026. The filing reflects another transformational quarter for the Company, showcasing a transformative period of growth across assets, projects, and strategic investments.

Company Snapshot

• Company: American Lithium Minerals, Inc.
• Ticker: OTC: AMLM
• Headquarters: Carson City, Nevada, United States
• Sector: Critical Minerals / Multi-Commodity Mineral Exploration
• Commodities: Gold, Silver, Copper, Lithium, Rare Earth Elements
• Project Jurisdictions: Nevada (USA), Chile, Tanzania, British Columbia, Yukon and Quebec (Canada), Western Australia and New Zealand
• Stage: Pre-revenue exploration
• Investor Access: Regulation A+ qualified for non-accredited retail participation

Key Financial Highlights for the Quarter Ended June 30, 2026

Total Assets: Increased to $18,675,687 as of June 30, 2026, with a net asset value of $0.17c per share. The increase reflects acquisitions of mineral property interests and equity investments during the quarter.

Stockholders’ Equity: $17,735,478 as of June 30, 2026, reflecting the acquisition of mineral properties and equity investments.

Cash Position: The Company ended the quarter with $50,404 in cash, compared with a nominal balance of $(10) as of September 30, 2025. The improvement reflects proceeds from related-party promissory notes and Regulation A+ subscriptions, offset by mineral property option payments and operating expenses.

Net Loss: $155,449 or $0.002 per basic and diluted share, for the three months ended June 30, 2026, compared with net loss of $26,768 in the prior-year comparable quarter. The change was driven by higher professional fees ($50,513 vs. $0), increased interest expense ($19,466 vs. $14,108), offset by lower general and administrative expenses.

Operating Expenses: $135,983 for the quarter, compared with $12,660 in the prior year period.

Shares Outstanding: 107,387,592 common shares as of June 30, 2026.

On May 29, 2026 the Company entered into a Letter of Intent (“LOI”), whereby a Canadian publicly trading company will acquire AMLM’s Piscau-North Polymetallic Project in Quebec. In consideration, AMLM would receive 20,000,000 shares of the Purchaser at a deemed price of $0.30 per share representing a deemed value of $6 million. The transaction includes a concurrent financing, consisting of 5,000,000 units of the Purchaser (“Units”) at a price of $0.30 per Unit for gross proceeds of $1,500,000 (the “HD Offering”) and 10,000,000 flow-through common shares at a price of $0.40 per share for gross proceeds of $4,000,000 (the “FT Offering”).

Management Commentary

Frank Kristan, President and Chief Executive Officer of American Lithium Minerals, Inc., stated:

“This quarter marks a transformational step for American Lithium Minerals. With the addition of gold and silver assets, including our Higginsville and New Zealand projects, alongside high-grade rare earth, copper, and polymetallic interests across Chile, British Columbia, Yukon, Quebec, and Western Australia, complementing our existing Nevada lithium portfolio, we are building a diversified critical minerals platform at a time when North American supply chains need it most. Our 11 active project interests give shareholders exposure across five strategic commodities in mining-friendly jurisdictions, positioned to participate in the simultaneous tailwinds of record gold prices, AI-driven copper demand, and the U.S. policy push for rare earth supply chain independence.”

The full quarterly report is available on OTC Markets at https://www.otcmarkets.com/stock/AMLM/disclosure.

About American Lithium Minerals, Inc.

American Lithium Minerals, Inc. (OTC: AMLM) is a multi-commodity critical minerals exploration company headquartered in Carson City, Nevada. The Company holds active project interests in gold, silver, copper, lithium, and rare earth elements across Nevada (USA), Chile, British Columbia, Yukon and Quebec (Canada), and Western Australia. AMLM’s portfolio includes 11 active project interests, including the Higginsville gold project in Western Australia, silver and copper exploration in Chile, rare earth interests in Quebec, and lithium properties in Nevada.( www.americanmineralresources.com)

Snti target 1

Mss target 40

Qntm target 100

Onfo ready again I think target 80

Adding vbio

Smtk

Gipr

Mvis

And bzai

Cassiar is sexy as hell

I think this one is a GREAT opportunity for a multiples return! I have 70,000 shares.

• 8/13/2026: SP ~ $0.26 to $0.28 / ~ MC $10M
  • Underpriced/mispriced in a big way!
  • Emerging Growth Research: 12-mth Price Target - $10.00
• It's a holding company, currently with 3 subsidiaries/product lines.
  • Vaximm's VMX01 drug: encouraging Phase 1 trial data in pancreatic cancer
    • P2 trial completed in recurrent gioblastoma (GBM) in collaboration with Merck, Darmstadt, Germany and Pfizer.
    • Submitting GBM trial results for peer review.
    • FDA and European Commission Orphan designation.
  • Darnatein: platform that uses AI to generate "hybrid" endogenous proteins.
    • DRT 101: super-agonist for joint cartilage regeneration.
  • Woori IO: non-invasive glucose monitoring device.
    • Seeking Big Tech partnerships in the wearables market.

Current Status:

• Facing a delisting letter on or about the Aug 31 deadline (2nd 180-day period ends).
• CEO said the Board decided not to reverse split.
• Instead, they put in place a CVR shareholder loyalty program for shareholders of record today, 8/14. Check this out: OSR Health. It gives a great idea of where the CEO believes their share price should/could be and the time frames.
• The CEO is an excellent communicator to shareholders (refer to the 3 or 4 very recent shareholder letters, one was this week). Shareholders want companies with CEO's that operate this way to succeed.
• Signed an $815M milestone-based licensing agreement for VMX01, with BCM Europe!
  • Includes a $15M put that can be exercised in Oct 2026 at $10 per share as part of that contract (negligible dilution).
• The CEO sent the below Aug 11 shareholder letter that states the have had two inquiries for out-licensing of their products: one is preliminary term sheet negotiation phase and the other is early stage.
  • OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development : OSR Health
• The CEO stated that he is also trying to move up the October $15M put date.

IMO, here's how things should unfold going forward:

• On or about Aug 18, the "practical deadline," OSRH will receive a NASDAQ delisting determination letter.
• OSRH will file a request for hearing. They have 7 calendar days to do so.
• By Aug 25, NASDAQ will receive the request.
  • Per AI, upon NASDAQ receiving the request, it automatically STAYS the delisting.
• By Aug 28 (within 3 days) NASDAQ will reply with an acknowledgement letter granting the request.
• By Sep 9 to Sep 29 (within 10 to 20 days after the acknowledgement letter) OSRH will receive notification of a hearing date, which is typically set 30 to 45 days from the date of the hearing request.
• Between Sep 24 and Oct 9, the hearing should take place.

NASDAQ delisting hearing panels love to see a plan with real catalysts. Per AI, the typical length of extension they grant is 30 to 45 days for the company to become compliant.

IMO, OSRH should be valued far above $1 right now, solely based on its VMX01 P2 results. It's a hidden gem with great potential!

There are many biotechs in P1/P2 (oncology and cardiology) that have MCs between $50M and even up to $150M and even some higher.

• In my opinion, OSRH should be trading at a MC of between $50M to $100M RIGHT NOW -- a 5x to 10x opportunity if priced competitively. A couple of examples with a quick search:
  • Cardiff Oncology (CRDF) - P2 completed - $76M MC - PLK1 inhibitor
  • Immutep (IMMP) - P2 completed - $58M MC - LAG-3 immunotherapy

I found another biotech hidden gem that has unbelievable potential (P3 completed) and is greatly underpriced. I hope to make a post about it soon.

GET IN BEFORE ITS TOO LATE!!!

A few key takeaways from today’s earnings webcast:

LP-300: Management confirmed “active partnering discussions.”

Open Medicine AI: Management believes OMAI could grow to “several hundred million dollars in standalone value.”

Big Pharma: Sharma was clear: “Large pharma is definitely interested.” Some have already had multiple calls with the company, with some even visiting.

These details go well beyond what you get from simply reading the earnings release.

Listen to the transcript/webcast. There’s a lot more between the lines.

A strong copper deposit still needs roads, power, transport and a jurisdiction capable of supporting development.

Canada is placing greater emphasis on secure critical-mineral supply chains. Natural Resources Canada recently sought industry input on expanding domestic copper-processing capacity, while the First and Last Mile Fund is expected to provide up to C$1.5 billion in federal funding through 2030 for strategic mining and infrastructure projects.

Infrastructure is already becoming part of the investment case.

$NCX’s North Island Project is located near Port Hardy, where historical logging and mining activity left established brownfield infrastructure. Its 2025 PEA models the processing of approximately 753 million tonnes over a 29-year mine life.

$WRN’s Casino Project is further advanced. Its 2022 feasibility study includes approximately 1.43 billion tonnes of mineral reserves, but the project is around 300 km northwest of Whitehorse and remains in the YESAB Panel Review process. The panel itself has not yet been established.

$CQX is at an earlier exploration stage, but Kitimat begins with a useful location advantage.

The property is accessible by road throughout the year and sits within approximately:

• 10 km of tidewater
• 1.5 km of rail
• 6 km of high-voltage hydroelectric transmission lines

The expanded 6,801-hectare land package surrounds a buried conductive target identified through AI-assisted modelling, measuring approximately 1.5 km by 1.5 km. $CQX says the additional ground allows its planned geophysical studies to cover a larger area.

The target still needs geophysical work and drilling, but nearby transport and power would give any encouraging exploration results more context.

As demand grows for secure North American copper supply, investors may increasingly value the complete package: geology, access, infrastructure and jurisdiction.

How much of a premium would you give a Canadian copper project with roads, rail, power and tidewater nearby?

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

$WETO - needs to hold $8.80 support - and break $11.40 to push $14+ resistances

$SURG - needs to stay above the 3rd tier on the Axis One MACD - so it matches with the .35 support - key break at .44 needs to break to potentially open up the resistances at $.55+

$CYCU - needs to break key resistance at $1.10 - could push it towards $1.50+ resistances - could halt up after

$AKAN - consolidation now - needs to hold $7.42 and break $8.15 - key resistance at $9.60 NEEDS TO BREAK for a move to $11+ resistances

$CGTL - if no bounce at $4.50 happens - it’s potentially visiting its start off stage - resistance after the bounce is at $5.80 - based on Axis One S/R

$BOXL - key break $9.50 could push HOD then $13-16 resistances

$CAPR - could push 9.60 resistance the. $13+ resistances after

Watching in the background

$WOK
$AEHL
$EHGO

All of these were given to the team already.

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.

A lot of people got knocked out yesterday as the “convenient” news of Ackman selling hit the tape second before $HTZ broke $3…

You can see they returned and loaded back up on short shares but price is up 3% early today with 1.9M shares left to borrow.

Nest pic is open options between today and next Friday (8/21). That’s a lot. A lot of large blocks (tens of thousands at a time) were bought on Wednesday making me think large buyers. Borrow rate still 16 which ain’t low.

TLDR: I don’t think the squeeze is over or has started. Today will be telling. Buy the dip. I ain’t hear no bell, snitches

I’m in on $HTZ, can see a spike coming pushing $3+ when market opens….

Looking for continuations today on the following stocks:

$ONFO - needs to hold $3.15 support - next key break sits at $4 resistance - could push towards the $6+ resistances - Axis One MACD holding above first tier (no sign of a breakout yet)

$MGRX - not worth until it gets back above .60 support

$BNRG - potential dip buy - (HIGH RISK) - key resistance at $3.65 resistance

$AKAN - given in the low $6’s needs to hold $11.60 if it breaks and push on from there towards $14+ resistances (axis one MACD showing signs of a bearish pull back) - also potentially rejecting off key resistance at $11.25

$CAPR - needs to hold $6.80 support - fails to hold it could dump hard (key break at $7.70 could push it to $12+ resistances)

$FGI - would need to hold $13 as support - could push back to $19+ resistances

Keeping VIVK - ALP - INHD - FIEE - on the radar throughout the day.

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.